利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.029 秒)

    CLEARANCE OF ABNORMAL IGA1 IN IGA1 DEPOSITION DISEASES
    1.
    发明申请
    CLEARANCE OF ABNORMAL IGA1 IN IGA1 DEPOSITION DISEASES 有权
    异常IGA1在IGA1沉积疾病中的清除

    公开(公告)号：US20090317381A1

    公开(公告)日：2009-12-24

    申请号：US12094145

    申请日：2006-11-17

    申请人： Andrew G. Plaut ,  Jiazhou Qiu

    发明人： Andrew G. Plaut ,  Jiazhou Qiu

    IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K9/00 ,  A61K38/14 ,  A61P37/00

    CPC分类号： C07K16/4283 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/55

    摘要： The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof.

    摘要翻译： 本发明涉及与IgA1特异性结合且已被修饰为包含O-或N-连接的聚糖的蛋白质。 本发明包括通过向个体施用本发明的聚糖修饰的IgA1结合蛋白来降低个体中IgA1，优选异常糖基化的IgA1的方法。 本发明还包括用于治疗以IgA1沉积为特征的疾病的方法，其中向有需要的个体施用聚糖修饰的IgA1结合蛋白。

    Method of regulating glucose metabolism, and reagents related thereto
    2.
    发明授权
    Method of regulating glucose metabolism, and reagents related thereto 有权
    调节葡萄糖代谢的方法及与其相关的试剂

    公开(公告)号：US06803357B1

    公开(公告)日：2004-10-12

    申请号：US09601432

    申请日：2001-01-05

    申请人： William A. Bachovchin ,  Andrew G. Plaut ,  Daniel Drucker

    发明人： William A. Bachovchin ,  Andrew G. Plaut ,  Daniel Drucker

    IPC分类号： A61K3804

    CPC分类号： A61K38/05 ,  A61K31/00 ,  A61K31/155 ,  A61K31/40 ,  A61K31/401 ,  A61K31/4025 ,  A61K31/675 ,  A61K31/69 ,  A61K31/702 ,  A61K38/005 ,  A61K38/28 ,  A61K38/55 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention provides methods and compositions for modification and regulation of GLP 1 metabolism, glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. The compositions described herein are high-affinity boronyl and non-boronyl peptidomimetic inhibitors of DPIV.

    摘要翻译： 本发明提供了用于修饰和调节GLP 1代谢，葡萄糖和脂质代谢的方法和组合物，通常降低胰岛素抵抗，高血糖症，高胰岛素血症，肥胖症，高脂血症，高脂蛋白血症（如乳糜微粒，VLDL和LDL）和调节体内 脂肪和更一般的脂质储备，更一般地，用于改善代谢障碍，特别是与糖尿病，肥胖和/或动脉粥样硬化相关的那些。 本文所述的组合物是DPIV的高亲和力硼烷和非硼酰肽模拟抑制剂。

    Surfactants and emulsifying agents to inhibit Helicobacter
    3.
    发明授权
    Surfactants and emulsifying agents to inhibit Helicobacter 失效
    表面活性剂和乳化剂抑制幽门螺杆菌

    公开(公告)号：US5534544A

    公开(公告)日：1996-07-09

    申请号：US293690

    申请日：1994-08-19

    申请人： Andrew G. Plaut ,  Anne V. Kane

    发明人： Andrew G. Plaut ,  Anne V. Kane

    IPC分类号： A61K31/765 ,  A61K31/77 ,  A61K31/23

    CPC分类号： A61K31/765 ,  A61K31/77

    摘要： A method of inhibiting the growth of Helicobacter pylori is described. The method involves administering to a mammal a composition containing a surfactant/emulsifying agent and which is substantially free of calcium, magnesium, aluminum and silicon ions.

    摘要翻译： 描述了抑制幽门螺杆菌生长的方法。 该方法包括向哺乳动物施用含有表面活性剂/乳化剂并且基本上不含钙，镁，铝和硅离子的组合物。

    Protease inhibitors
    4.
    发明授权
    Protease inhibitors 失效
    蛋白酶抑制剂

    公开(公告)号：US4935493A

    公开(公告)日：1990-06-19

    申请号：US105768

    申请日：1987-10-06

    申请人： William W. Bachovchin ,  Andrew G. Plaut ,  Charles A. Kettner

    发明人： William W. Bachovchin ,  Andrew G. Plaut ,  Charles A. Kettner

    IPC分类号： C07K5/06 ,  C07K5/08

    CPC分类号： C07K5/0827 ,  C07K5/0606 ,  C07K5/06191

    摘要： A compound having the structure ##STR1## where T is of the fomrula ##STR2## where each D.sup.1 and D.sup.2, independently, is a hydroxyl group of a group which is capable of being hydrolysed to a hydroxyl group in aqueous solution at physiological pH; a group of the formula ##STR3## where G is either H,F or an alkyl group containing 1 to about 20 carbon atoms and optional heteroatoms which can be N, S, or O; or a phosphonate group of the formula ##STR4## where J is O-alkyl, N-alkyl, or alkyl, each comprising about 1-20 carbon atoms and, optionally, heteroatoms which can be N, S, or O; T being able to form a complex with the catalytic site of an enzyme, X is a group having at least one amino acid, ##STR5## and each R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 is separately a group which does not interfere significantly (i.e., does not lower than Ki of the compound to less than 10.sup.-7 M) with site-specific recognition of the compound by the enzyme, and allows a complex to be formed with the enzyme.

    摘要翻译： 具有结构的化合物，其中T是所述的“IMAGE”，其中每个D1和D2独立地是能够在生理pH下在水溶液中水解成羟基的基团的羟基; 其中G是H，F或含有1至约20个碳原子的烷基和可以是N，S或O的任选的杂原子的式 或其中J为O-烷基，N-烷基或烷基的式（IMAGE）的膦酸酯基团，各自包含约1-20个碳原子，以及任选的可以是N，S或O的杂原子; T能够与酶的催化位点形成复合物，X是具有至少一个氨基酸的基团，每个R 1，R 2，R 3，R 4，R 5，R 6，R 7和R 8 分别是通过酶对化合物的位点特异性识别而不会显着干扰（即不低于化合物的Ki至小于10-7M）的基团，并且允许与酶形成复合物。

    Clearance of abnormal IGA1 in IGA1 deposition diseases
    5.
    发明授权
    Clearance of abnormal IGA1 in IGA1 deposition diseases 有权
    IGA1沉积病异常IGA1的清除

    公开(公告)号：US08440191B2

    公开(公告)日：2013-05-14

    申请号：US12094145

    申请日：2006-11-17

    申请人： Andrew G. Plaut ,  Jiazhou Qiu

    发明人： Andrew G. Plaut ,  Jiazhou Qiu

    IPC分类号： A61K39/395

    CPC分类号： C07K16/4283 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/55

    摘要： The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof.

    摘要翻译： 本发明涉及与IgA1特异性结合且已被修饰为包含O-或N-连接的聚糖的蛋白质。 本发明包括通过向个体施用本发明的聚糖修饰的IgA1结合蛋白来减少个体中IgA1，优选异常糖基化的IgA1的方法。 本发明还包括用于治疗以IgA1沉积为特征的疾病的方法，其中向有需要的个体施用聚糖修饰的IgA1结合蛋白。

    Combination therapy with IgA1 proteases
    8.
    发明授权
    Combination therapy with IgA1 proteases 有权
    IgA1蛋白酶联合治疗

    公开(公告)号：US08216568B2

    公开(公告)日：2012-07-10

    申请号：US12177125

    申请日：2008-07-21

    申请人： Andrew G. Plaut ,  Jiazhou Qiu

    发明人： Andrew G. Plaut ,  Jiazhou Qiu

    IPC分类号： A61K38/48

    CPC分类号： C12N9/52 ,  C07K2319/21 ,  C07K2319/40 ,  C07K2319/42 ,  C07K2319/43

    摘要： The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.

    摘要翻译： 本发明公开了使用细菌IgA1蛋白酶处理组织和器官中的IgA1沉积。 细菌IgA1蛋白酶特异性切割IgA1分子，从而提供特异性切割和去除IgA1沉积的手段。 因此，提供了用于治疗以IgA沉积为特征的疾病的治疗剂。 特别地，公开了治疗IgA肾病，疱疹样皮炎（DH）和紫癜性紫癜（HS）的治疗剂。

    Inhibitors of dipeptidyl-aminopeptidase type IV
    10.
    发明授权
    Inhibitors of dipeptidyl-aminopeptidase type IV 失效
    II型二肽基氨基肽酶的抑制剂

    公开(公告)号：US07230074B2

    公开(公告)日：2007-06-12

    申请号：US10775598

    申请日：2004-02-10

    申请人： William W. Bachovchin ,  Andrew G. Plaut ,  George R. Flentke

    发明人： William W. Bachovchin ,  Andrew G. Plaut ,  George R. Flentke

    IPC分类号： C07K5/10

    CPC分类号： C07F5/025

    摘要： Peptide inhibitors of dipeptidyl-aminopeptidase type IV (DP-IV) are provided. The peptide inhibitors have an isomeric purity of about 96–99 percent. The peptide inhibitors include one or more amino acids covalently coupled to boroproline moiety. The compounds are useful as DP-IV inhibitors, in vivo and in vitro.

    摘要翻译： 提供IV型二肽基氨基肽酶（DP-IV）的肽抑制剂。 肽抑制剂的异构纯度约为96-99％。 肽抑制剂包括共价偶联到硼脯氨酸部分的一个或多个氨基酸。 该化合物在体内和体外可用作DP-IV抑制剂。